BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10938510)

  • 1. Long term follow-up of patients with chronic hepatitis C treated with interferon alpha.
    Collier JD; Adams PA; Feinman V; Ghent C; Witt-Sullivan H; Minuk G; Krajden M; Heathcote J
    Can J Gastroenterol; 2000; 14 Suppl B():77B-80B. PubMed ID: 10938510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B.
    Sim H; Yim C; Krajden M; Heathcote J
    Am J Gastroenterol; 1998 Jan; 93(1):39-43. PubMed ID: 9448171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
    J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
    Pockros PJ; Tong M; Lee WM; van Leeuwen DJ; Keeffe EB; Bala K; Killenberg PG; Foust RT; Rosenblate HJ; Payne KM; Fromm H; Lesesne HR; Black M
    J Viral Hepat; 1998 Jul; 5(4):271-6. PubMed ID: 9751014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy.
    Arase Y; Ikeda K; Chayama K; Murashima N; Tsubota A; Nakamura I; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Kobayashi M; Kumada H
    J Gastroenterol; 1999 Oct; 34(5):594-9. PubMed ID: 10535487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.
    Chemello L; Cavalletto L; Bernardinello E; Boccato S; Casarin P; Cavinato F; Urban F; Pontisso P; Cecchetto A; Gatta A; Alberti A
    J Viral Hepat; 1999 Jul; 6(4):321-7. PubMed ID: 10607247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
    Formann E; Steindl-Munda P; Hofer H; Jessner W; Bergholz U; Gurguta C; Ferenci P
    Aliment Pharmacol Ther; 2006 Feb; 23(4):507-11. PubMed ID: 16441471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis C long-term responders to human leukocyte interferon-alpha therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance.
    Morisco F; Tuccillo C; Iasevoli P; Sessa G; Brunasso G; Caporaso N
    Eur J Gastroenterol Hepatol; 1998 May; 10(5):399-403. PubMed ID: 9619386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients.
    Fallows G; Kaita K; Minuk G; Penner F; Smart G; Dawood M; Rosser B
    Can J Gastroenterol; 2000; 14 Suppl B():30B-35B. PubMed ID: 10938502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.
    Larghi A; Tagger A; Crosignani A; Ribero ML; Bruno S; Portera G; Battezzati PM; Maggioni M; Fasola M; Zuin M; Podda M
    J Med Virol; 1998 May; 55(1):7-11. PubMed ID: 9580879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
    Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
    Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
    Reichard O; Glaumann H; Frydén A; Norkrans G; Wejstål R; Weiland O
    J Hepatol; 1999 May; 30(5):783-7. PubMed ID: 10365802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.
    Maylin S; Martinot-Peignoux M; Ripault MP; Moucari R; Cardoso AC; Boyer N; Giuily N; Castelnau C; Pouteau M; Asselah T; Nicolas-Chanoine MH; Marcellin P
    Liver Int; 2009 Apr; 29(4):511-7. PubMed ID: 19076273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy.
    Tsuda N; Yuki N; Mochizuki K; Nagaoka T; Yamashiro M; Omura M; Hikiji K; Kato M
    J Med Virol; 2004 Nov; 74(3):406-13. PubMed ID: 15368524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy.
    García-Bengoechea M; Basaras M; Barrio J; Arrese E; Montalvo II; Arenas JI; Cisterna R
    Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.